The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin

Frank L. Rice1,2*, George Houk1, James P. Wymer3, Sara J. C. Gosline4, Justin Guinney4, Jianqiang Wu5, Nancy Ratner6, Michael P. Jankowski6,7, Salvo La Rosa8, Marilyn Dockum1, James R. Storey9, Steven L. Carroll10, Phillip J. Albrecht1,2, Vincent M. Riccardi11

1 Integrated Tissue Dynamics LLC, Rensselaer, NY, United States of America, 2 Division of Health Sciences, State University of New York at Albany, Albany, NY, United States of America, 3 Department of Neurology, University of Florida, Gainsville, FL, United States of America, 4 Sage Bionetworks, Seattle, WA, United States of America, 5 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital, University of Cincinnati, Cincinnati, OH, United States of America, 6 Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, United States of America, 7 Department of Anesthesiology, Division of Pain Management, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, United States of America, 8 Children’s Tumor Foundation, New York, NY, United States of America, 9 Department of Neurology, Albany Medical College, Albany, NY, United States of America, 10 Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States of America, 11 The Neurofibromatosis Institute, La Crescenta, CA, United States of America

* FrankRice@INTiDYN.com

Abstract

In addition to large plexiform neurofibromas (pNF), NF1 patients are frequently disfigured by cutaneous neurofibromas (cNF) and are often afflicted with chronic pain and itch even from seemingly normal skin areas. Both pNFs and cNF consist primarily of benign hyperproliferating nonmyelinating Schwann cells (nSC). While pNF clearly arise within deep nerves and plexuses, the role of cutaneous innervation in the origin of cNF and in chronic itch and pain is unknown. First, we conducted a comprehensive, multi-molecular, immunofluorescence (IF) analyses on 3mm punch biopsies from three separate locations in normal appearing, cNF-free skin in 19 NF1 patients and skin of 16 normal subjects. At least one biopsy in 17 NF1 patients had previously undescribed micro-lesions consisting of a small, dense cluster of nonpeptidergic C-fiber endings and the affiliated nSC consistently adjoining adnexal structures—dermal papillae, hair follicles, sweat glands, sweat ducts, and arterioles—where C-fiber endings normally terminate. Similar micro-lesions were detected in hind paw skin of mice with conditionally-induced SC Nf1-/- mutations. Hypothesizing that these microlesions were pre-cNF origins of cNF, we subsequently analyzed numerous overt, small cNF (s-cNF, 3–6 mm) and discovered that each had an adnexal structure at the epicenter of vastly increased nonpeptidergic C-fiber terminals, accompanied by excessive nSC. The IF and functional genomics assays indicated that neurturin (NTRN) and artemin (ARTN) signaling...
Competing interests: FLR and PJA are the co-founders and co-owners of INTiDYN, which is a for-profit contract and private equity research and consulting organization. GH and MD are research employees of INTiDYN. INTiDYN has no other commercial affiliations but does conduct contract research for pharmaceutical companies and academic collaborators unrelated to, and having no conflict of interest in this research. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Abbreviations: AVS, Arteriole-Venule Shunt; BCC, Boundary Cap Cell; CGRP, Calcitonin Gene-Related Product; cNF, Cutaneous Neurofibroma; cRET, RET Proto-Oncogene; DAPI, 4',6-diamidino-2-phenylindole, dihydrochloride; FNE, Free Nerve Ending; GAP-43, Growth-Associated Protein 43; GDNF, Glial-Derived Neurotrophic Factor; GFRα1, Glial-Derived Neurotrophic Factor Family Receptor alpha; IF, Immunofluorescence; MBP, Myelin Basic Protein; MC, Mast Cell; nSC, nonmyelinating Schwann Cell; NF1, the non-human mammalian gene/locus (italicized); NF1, the human gene/locus (italicized) and the syndrome (non-italicized); NF200, 200kD neurofilament protein; NGF, Nerve Growth Factor; NGFR, Nerve Growth Factor Receptor, also referred to as p75; NRG-1, Neuregulin; NRTN, Neurturin; NSE, Neuron-Specific Enolase; pChAT, peripheral Choline-Acetyl Transferase; PGP, Protein Gene Product 9.5; pre-cNF, Cutaneous Pre-neurofibroma; PSPN, Persephin; SC, Schwann Cell; SKP, Skin-derived Precursor; TGFβ1, Transforming Growth Factor Beta 1; VACHt, Vesicular Acetylcholine Transporter.

Introduction

Multiple cutaneous neurofibromas (cNF) are characteristic of neurofibromatosis type 1 (NF1) patients who have an autosomal dominant loss-of-function mutation of an NF1 allele. cNF are visibly protruding masses in the skin composed of a complex mixture of hyperproliferating Schwann cells (SC), particularly nonmyelinating SC (nSC), intermingled with fibroblasts, vascularule, macrophages, mast cells and other cellular components [1–5]. This composition is similar to another hallmark of NF1, which are the expansive growths within large nerves and plexuses referred to as plexiform neurofibromas (pNF).

Although their histologic and genomic abnormalities are similar [1, 3, 6], the natural history of cNF and pNF is quite distinct. While pNF often present as congenital lesions, cNF are typically not present at birth [1, 2]. Instead, cNF usually begin to appear at puberty, accumulating thereafter to a variable degree over the remainder of the patient’s life. In addition, whereas pNF occasionally transform into malignant peripheral nerve sheath tumors, cNF have little, if any, malignant potential [1, 2, 7]. Finally, whereas pNF clearly originate within nerves and plexuses, the origin of cNF remains uncertain particularly in relation to cutaneous innervation [1, 8, 9].

The precise nature of cNF has long been debated, originally considered by many to be dysplasias, hamartomas or a dysfunctional wound-healing process [10–13]. However, over the last decade emphasis has been on cNF as “true” neoplasms [6, 14]. This is based on evidence in human cNF and pNF of a “second hit” diploinsufficient (DI) mutation of the remaining functional NF1 allele in the SC of the lesions [15–18], with little evidence of this occurring among other cell types such as fibroblasts. These other cell types may be passively engulfed or actively recruited into the growing pNF and cNF in response to trophic factors secreted by the hyperproliferating DI nSC [19]. However, whereas mouse models with SC-specific diploid Nf1 ablations develop pNF analogous to those seen in human NF1 patients, there had been little indication of human-like cNF in these animals [20, 21], which suggests that pNF and cNF have distinct origins.

A key clinical observation has been typically overlooked in considering the potential origin of cNF, which is NF1 patients are often afflicted with chronic itch and pain involving the skin that is independent of and even precedes the overt appearance of cNF [2, 22–25]. These sensations have largely been assumed to originate from nerve irritations caused by detected or undetected pNF, although itch has been attributed to mast cells within cNF [26–29]. However, little attention has been paid to what role, if any, that cutaneous innervation plays in the pathogenesis of cNF. Even the presence and extent of cutaneous innervation in cNF has barely been investigated [30].

To determine whether there is anything about the cutaneous innervation that was prescient to the evolution of cNF or neuropathic symptoms, we conducted an in-depth investigation of the cutaneous innervation in 3mm skin punch biopsies taken from three locations in normal appearing glabrous and hairy skin (at least 1 cm from the nearest cNF) in nineteen NF1
patients as compared to the innervation in comparable biopsies from sixteen normal volunteers. These analyses were performed with a comprehensive, integrated, multi-molecular immunofluorescence (IF) research platform referred to as the INTiDYN ChemoMorphometric Analysis (ITD-CMA) that has evolved over decades of research on normal and pathological cutaneous innervation [31–37]. ITD-CMA is an enhanced approach to the increasing use of skin biopsies to elucidate potential cutaneous mechanisms of chronic pain associated with a variety of neuropathic pain disorders [38–43].

Materials and methods
The human research protocols were approved by the Saint Peter’s Hospital (Albany, NY) IRB for skin biopsies and by the Western IRB for collection of small cNF (s-cNF). All subjects gave written informed consent to the collection and use of the skin biopsies and cNF for research purposes. Skin biopsies, 3mm in diameter, and s-cNF were obtained by established procedures and appropriate monitoring [35]. No adverse events occurred as a result of skin biopsy and s-cNF collection procedures.

Biopsy specimen
Skin biopsies were collected from 19 NF1 patients (20–64 years old; Fig 1) and 16 genetically and somesthetically normal subjects (24–70 years old). Both groups had a similar proportion of males and females. Following clinical assessments, 3 mm skin punch biopsies were obtained under local lidocaine anesthesia from three locations of normal appearing skin (at least 1 cm from the nearest cNF) of each NF1 patient and three comparable locations of each normal subject. As assessed by ITD-CMA in prior unrelated human studies [35, 36, 39, 41], the three biopsy locations were: hypothenar palmar glabrous skin, hypothenar dorsal hairy skin, and

![Image](https://doi.org/10.1371/journal.pone.0216527.g001)
distal leg hairy skin above the lateral malleolus. Following previously published procedures [34, 35], the biopsies were immediately immersion-fixed in 4% paraformaldehyde in 0.1M phosphate buffered saline (PBS) at pH 7.4 for 4 hours at 4°C, then rinsed and stored in PBS at 4°C. In addition, twenty s-cNF (3-6mm in diameter) surgically removed from the backs of two other female NF1 patients (32 and 35 years old) were supplied from the tissue bank maintained by the Children’s Tumor Foundation (New York, NY). These neurofibromas had been fixed overnight in 10% neutral formalin then rinsed and stored in 70% ethanol. Upon receipt at INTiDYN, the s-cNF were rinsed and stored in PBS at 4°C. Additional s-cNF from these same two NF1 patients and 11 others were flash-frozen to obtain total mRNA and sent to Sage Bio-networks (Seattle, WA) for quantitative transcriptomic functional analyses [44].

Immunofluorescence

Following the ITD-CMA multi-label IF procedures [34, 35], the NF1 patient skin biopsies, normal subject skin biopsies, and s-cNF were cryoprotected in 30% sucrose/PBS, mounted in optimal cutting temperature media, and frozen sectioned by cryostat at a 14 μm thickness. Consecutive sections were thaw-mounted, rotated sequentially across a series of at least 20 slides, such that each slide contained numerous sections from equally spaced intervals throughout the entire biopsy. The NF1 patient biopsies, normal subject biopsies, and 10 of the s-cNF were sectioned perpendicular to the skin surface. The remaining 10 s-cNF were sectioned parallel to the skin surface. All specimens were processed for integrated IF assessments using several double-label combinations of primary antibodies on alternating sections. The primary antibodies were chosen to elucidate the structural and neurochemical properties of the innervation and other components of the skin and s-cNF (Table 1). In particular, the Protein Gene Product 9.5 (PGP) antibody, which is directed against ubiquitin-C-terminal hydrolase (UCHL1), labels all cutaneous innervation. All primary antibodies were visualized by labeling with species appropriate donkey secondary antibodies conjugated with Cy3 for red fluorescence and Alexa488 for green fluorescence (Table 1) and all slides were counterstained stained with 4’,6-diamidin-2-phenylindole hydrochloride (DAPI) to reveal cell nuclei in blue fluorescence. The primary antibodies had been previously validated and used in previous studies of mouse, rat, monkeys, and humans, so controls for this study were omission of the primary antibodies on sections of the cNF, which had never been analyzed before.

Digital imaging

High resolution epifluorescence images were captured utilizing an Olympus BX51 microscope equipped with a Hamamatsu ER camera or an Olympus Optical Provis AX70 microscope equipped with a Hamamatsu C11440 camera (e.g., Figs 2–8). Each microscope system was equipped with conventional fluorescence filter cubes for specific excitation and emission spectra required for blue/green/red fluorophore channel separation, a linear focus encoder, and a 3-axis motorized stage, interfaced with NeuroLucida software (MBF Bioscience, Essex, VT), enabling seamless high resolution whole section montages and complete off-line or real-time image mapping/measuring of selected elements. Image montages (e.g., Figs 6 and 7) were collected using identical camera settings for each label across the entire specimen cohort. Co-labeling for various antigens was assessed using the application Photoshop (Adobe Systems, San Jose, CA) to analyze each color channel. For these studies, the analysis consisted of visual interrogation of the biopsies to examine the morphological and immunocytochemical characteristics of s-cNF innervation and intrinsic cellular components. In all figures showing fluorescent immunolabeling, the antigens for the primary antibodies are indicated in the upper left corner in the color of the corresponding secondary
Table 1. Chemomorphometric analysis (CMA) antibody specifications.

| Antibody          | Species | Dilution | Source                           |
|-------------------|---------|----------|----------------------------------|
| CGRP              | rabbit  | 1:800    | Chemicon/Millipore [ab15360]    |
| CGRP              | sheep   | 1:500    | Abcam [ab22560]                 |
| cRET              | rabbit  | 1:250    | Abcam [ab134100]                |
| DjH               | rabbit  | 1:800    | Chemicon/Millipore [ab145]      |
| GAP-43            | rabbit  | 1:1000   | gift from David Schreyer        |
| GAP-43 (monoclonal)| mouse   | 1:400    | Abcam [ab12274]                 |
| GFRα1             | rabbit  | 1:50     | Abcam [ab8026]                  |
| GFRα1 (monoclonal)| mouse   | 1:200    | R&D Systems [mab560]            |
| GFRα2             | rabbit  | 1:50     | Abcam [ab8027]                  |
| GFRα2 (monoclonal)| mouse   | 1:200    | R&D Systems [mab613]            |
| GFRα3             | rabbit  | 1:50     | Abcam [ab8028]                  |
| GFRα3 (monoclonal)| mouse   | 1:200    | R&D Systems [mab6701]           |
| GFRα4 (monoclonal)| mouse   | 1:200    | R&D Systems [mab1439]           |
| MBP               | rabbit  | 1:1000   | Biogenesis [ab6420-2204]        |
| NF200             | rabbit  | 1:800    | Chemicon/Millipore [ab1989]     |
| NF200 (monoclonal)| mouse   | 1:400    | Sigma [ab142]                   |
| NGFR (p75) (monoclonal)| mouse | 1:40 | Abcam [ab3125] |
| NPY               | sheep   | 1:800    | Chemicon/Millipore [ab1583]     |
| NRG1              | rabbit  | 1:100    | Abcam [ab191139]                |
| NSE (monoclonal)  | mouse   | 1:100    | Abcam [ab16808]                 |
| pChAT             | rabbit  | 1:10,000 | gift from Hiroshi Kimura        |
| PECAM (monoclonal)| mouse   | 1:50     | DAKO [abMO823]                  |
| PGP9.5            | rabbit  | 1:800    | Cedarlane (UltraClone Ltd) [RA95101] |
| PGP9.5 (monoclonal)| mouse | 1:200 | Cedarlane (UltraClone Ltd) [31A3] |
| Si00Beta          | rabbit  | 1:500    | Abcam [ab55264]                 |
| Si00Beta (monoclonal)| mouse | 1:250 | Abcam [ab11178] |
| SOX10             | rabbit  | 1:200    | Abcam [ab18086]                 |
| TGFβ1 (monoclonal)| mouse   | 1:250    | Abcam [ab190503]                |
| TrkA              | sheep   | 1:500    | Abcam [ab72029]                 |
| TrpA1             | rabbit  | 1:400    | Astra-Zenea                     |
| TrpV1             | rabbit  | 1:500    | Abcam [ab3487]                  |
| VACHT             | goat    | 1:1000   | Santa Cruz Biotechnology [sc7717] |

**Cy3 secondary abs**

- goat IgG donkey 1:500 705-165-003
- rabbit IgG donkey 1:500 711-165-152
- sheep IgG donkey 1:500 713-165-003
- mouse IgG goat 1:500 115-165-003

**Alexa488 secondary abs**

- rabbit IgG donkey 1:250 A21202
- sheep IgG donkey 1:250 A21206
- mouse IgG donkey 1:250 A11015

**Histochemical Reagents**

| DAPI               | Dilution | Source          |
|--------------------|----------|-----------------|
|                   | 100ng/ml | Sigma [D-9542] |

All primary antibodies are polyclonal unless noted otherwise

https://doi.org/10.1371/journal.pone.0216527.t001
antibody. All primary antibodies were validated in prior studies among the various co-authors. Control sections from skin biopsies and s-cNF were processed only with secondary or no antibodies to assess for nonspecific secondary antibody immunolabeling or autofluorescence (Section A in S1 Text and S1 Fig).

Gene expression analysis

Independent from and blinded to the ITD-CMA results, gene expression measurements of select target genes were captured in up to four flash frozen s-cNF from each of the two NF1 patients that were the source of the s-cNF for the ITD-CMA analyses, as well as from each of 11 additional NF1 patients [44]. Specifically, normalized counts were visualized in a heatmap representation using the R heatmap function and library. To compare the relative expression of specified genes of interest in the s-cNF that are of interest based on the ITD-CMA results, a plot of the relative rank of each gene (x-axis) was created for each patient sample. The higher the rank, the more abundant the transcript was in that sample (Fig 9).
Published transcript levels were also compared to 33 normal skin controls derived from the ENCODE consortium using the LIMMA tool to identify genes that were differentially expressed between the cNF patient samples and the skin controls [45]. In total, 6996 genes out of 28,517 transcripts were differentially expressed (adj. \( p < 0.01 \)), suggesting a possible batch effect. However, differential expression values of those genes of particular interest based on ITD-CMA results are depicted in Fig 10. Genes that exhibit a negative log2 fold change are up-regulated in cNFs compared to normal skin.

https://doi.org/10.1371/journal.pone.0216527.g003

Fig 3. Immunofluorescence profile of pre-cNF among sweat ducts and glands. Immunolabeling of NF1 patient skin biopsies revealed pre-cNF engulfing sweat ducts (sd in B, C) and infiltrating sweat glands (sg in E, F). A, D: Innervation of sd and sg in normal subjects. The sweat ducts normally have an extremely sparse innervation with NF200-positive and NF200-negative fibers (A, B; yellow and green arrows) and virtually no fibers with CGRP (C; green arrow). Normal sweat gland tubules are each surrounded by a loose tangle of fibers of which nearly all revealed by PGP labeling (D-F; green arrows) are cholinergic sympathetic with a sparse contingent of sensory fibers that co-label for NF200 or CGRP (D-F; yellow arrows). In pre-cNF engulfing sweat ducts or embedded within sweat glands (dotted outlines), the densely packed, extremely small-caliber fibers labeled for PGP. A high proportion co-labeled with NF200 (E; yellow compared to green arrowheads). Very few co-labeled for CGRP (F; yellow arrowhead). Scale bar = 50 μm.
Mouse model

The DhhCre;Nf1<sup>β/β</sup> model was described previously [21]. All animal procedures were approved by the Animal Care and Use Committee of Cincinnati Children’s Hospital Medical Center. Mice were housed in temperature- and humidity-controlled facilities with 12-hour dark-light cycles and free access to food and water. Mice were largely on the C57Bl/6 strain background and were genotyped by PCR [46, 47]. Briefly, male DhhCre mice were bred onto the female Nf1<sup>fl/fl</sup> background to obtain the F1 generation (DhhCre;Nf1<sup>fl/+</sup>). Female Nf1<sup>fl/fl</sup> mice were then bred with male DhhCre;Nf1<sup>fl/+</sup> mice to obtain DhhCre;Nf1<sup>fl/fl</sup> mice. DhhCre;Nf1<sup>fl/+</sup> littermates were used as controls. Analyzed at 7–9 months old, DhhCre;Nf1<sup>fl/fl</sup> mice develop plexiform neurofibromas, and enlargements in cutaneous nerves described as Grade 1 neurofibroma with numerous spindle shaped S100+ cells, abundant collagen, and mast cells. Hindpaws from 4 of these DhhCre;Nf1<sup>β/β</sup> mice, that had been perfusion fixed with 4% PFA, were amputated at the ankle. The hairy dorsal skin and glabrous plantar skin was removed and was sectioned and processed for ITD-CMA as described above for the human skin biopsies.

Results

Detection and incidence of presumptive cNF precursors (pre-cNF)

In at least one biopsy from 17 of the 19 NF1 patients (Fig 1), immunolabeling for PGP9.5 revealed one or more micro-lesions containing small, discreet dense clusters of small-caliber...
nerve fibers (Figs 2–4, dotted outlines). The clustered nerve fibers immunolabeled for the axon growth marker GAP-43, consistent with axon sprouting (see below). Eventually interpreted as precursors to cNF (pre-cNF), these neural micro-lesions were not observed in any of the normal subject biopsies and had not been observed previously in other studies of pathological human skin biopsies [34, 35, 39, 41, 48]. Four patients had at least one micro-lesion in all three biopsies.

Nearly all of these micro-lesions were intimately associated with adnexal skin structures that are sites where various combinations of cutaneous innervation normally terminate [34, 36, 37, 49]. These adnexae included dermal papillae that invaginate into the epidermis (Fig 2A–2C), hair follicles (Fig 2D–2F), sweat ducts (Fig 3A–3C), sweat glands (Fig 3D–3F), and arterioles and arteriole-venule shunts (AVS) (Fig 4). A total of 45 microlesions were detected among all the biopsies from NF1 patients, with some biopsies containing more than one microlesion, each involving its own adnexa (Fig 1).

In each micro-lesion, S100B immunolabeling revealed numerous presumptive nSC intimately affiliated with the clustered innervation (Fig 5). Given that cNF are known to consist overwhelmingly of nSC, this suggested that the micro-lesions might be pre-cNF. Therefore, we

Fig 5. SC and other cells in pre-cNF. Immunolabeling revealed the presence in pre-cNF of abnormal concentrations of SC immunolabeled for S100B (A–C) and another non-neuronal cell type immunolabeled for NRG-1 (D–F). Inserts are 2X enlargements of sites in the small white rectangles. A-C: In this pre-cNF located at the edge of a sweat gland (sg), dense aberrant axons labeled for PGP are intimately lined with SC processes labeled with S100B (yellow arrowheads). S100B is expressed in SC bodies (red arrowheads). D-F: In this pre-cNF located at the edge of a small arteriole (art), S100B-labeled SC bodies and their processes (green arrowheads) are completely distinct from clusters of other cells with few processes that label for NRG-1 (red arrowheads). Scale bar = 50μm.
hypothesized that an adnexal structure would be present within overt s-cNF, accompanied by excessive innervation and nSC.

**Structural organization of s-cNF**

Consistent with the pre-cNF hypothesis, immunolabeling of serial sections from numerous 3–6 mm cNF, cut perpendicular or parallel to the skin surface (Figs 6 and 7, respectively),
Fig 7. Structural organization of an s-cNF around an adnexal core (parallel). Immunolabeling reveals the adnexal core of a 4mm s-cNF sectioned parallel to the epidermal surface and co-labeled for GAP-43 (green), S100B (red), and DAPI (blue). Small blood vessels filled with albumen autofluorescence (yellow arrow) A-C: Complete montages of 3 sections at successively deeper levels. The red contours outline the perimeter of a dense concentration of small-caliber fibers oriented circumferentially around a core. The area in the white square of A is shown at 2X magnification in D-F. D-F: Increased magnification reveals a sweat duct (white arrow) surrounded by small-caliber fibers cut in cross-section at the core. The fibers shift to a circumferential orientation around this core. S100B-labeled SC (E) intimately match the orientations and concentrations of the fibers labeled for GAP-43. The area in the white square of D is shown at still a 2X higher magnification in G-I. G-I: An increased magnification of the sweat duct and associated small-caliber fibers cut in cross-section at the core of the s-cNF. Insets in G-H are a further 2X magnification of the broken line area in G that show the intimate association of SC and their processes (red arrowheads) with the aberrant small-caliber fibers (green arrowheads). Scale bar = 500μm.

https://doi.org/10.1371/journal.pone.0216527.g007
revealed that each had an adnexal structure imbedded at the core that was associated with a massive dense concentration of aberrant innervation that extensively co-labeled for GAP-43 and PGP (Figs 7A–7C and 8A–8C). Numerous S100B-positive presumptive nSC were densely intermingled with the aberrant innervation (red and green arrowheads in Figs 7 and 8J–8L, respectively). The aberrant innervation ascended along or within the adnexal core structure.
and then expanded horizontally and circumferentially across the full width of the s-cNF. This organization was especially obvious in perpendicular sections demonstrating hair follicles and sweat ducts (Fig 6A, 6C and 6D). The lateral expansion was restricted to the loose reticular dermis, as though blocked and deflected from invading the thin, compact layer of papillary dermis. In some cases, a hair follicle was clearly the adnexal core (Fig 6C), but in other cases a hair follicle was entrapped by innervation originating and spreading from another adnexal structure, such as a deep sweat gland (Fig 6B).

Multi-molecular characterization of pre-cNF and s-cNF innervation

Normal innervation. The next objective was an in depth ITD-CMA characterization of the aberrant pre-cNF and s-cNF innervation using certain antibody combinations to identify different functional types of innervation, as documented in previous publications [31, 33–37, 49, 50]. Arrows in Figs 2–4 indicate how normal combinations of innervation appear in biopsy sections after immunolabeling. The known types of innervation terminating at the cutaneous adnexal target structures in normal skin include: 1) various types and combinations of sensory endings supplied by thin-caliber, unmyelinated axons (C fibers); 2) slightly larger caliber, thinly myelinated axons (A\(\delta\) fibers); and 3) much larger caliber, thickly myelinated axons (A\(\beta\) fibers).
fibers). Subsets of C and A\(\delta\) fibers are implicated in pain mechanisms and are referred to as nociceptors [49]. Additionally, sweat glands are also innervated mostly by thin-caliber, unmyelinated cholinergic sympathetic fibers, while arterioles and AVS are also innervated by thin-caliber, unmyelinated noradrenergic sympathetic fibers.

As documented previously for skin biopsies from normal subjects [34, 36, 37], all types of innervation immunolabeled for PGP9.5. Presumptive thin-caliber A\(\delta\) and large-caliber A\(\beta\) fibers co-labeled for 200 kD neurofilament protein (NF200; yellow arrows, Figs 2A, 2B and 2D–2F; 3A, 3B, 3D and 3E; 4A and 4C) and Myelin Basic Protein (MBP; not shown, but see S3D–S3F Fig). Presumptive C fibers lacked NF200 immunolabeling, and consisted of two major subtypes: 1) “peptidergic”, that co-labeled for CGRP, and 2) “nonpeptidergic” that lacked CGRP (yellow and green arrows, respectively; Figs 2C; 3C and 3F; 4B and 4D). As documented previously [36], sweat glands were densely innervated by small-caliber fibers (green and yellow arrows, Fig 2D) of which the vast majority were unmyelinated cholinergic sympathetic fibers that labeled for pChAT and VACHT (not shown). A small contingent consists of peptidergic and nonpeptidergic C fibers of which some immunolabeled for NF200 (yellow arrows, Fig 2D–2F). Arterioles and AVS also have a dense small-caliber innervation (green and yellow arrows, Fig 4A and 4B) which was mostly noradrenergic sympathetic fibers that co-labeled for DBH and NPY (not shown) [35, 36]. A large proportion was sensory consisting mostly of peptidergic C and A\(\delta\) fibers and a smaller proportion of nonpeptidergic C fibers (yellow arrows, Fig 4A and 4B).

As documented previously, virtually all thin-caliber sensory and sympathetic fibers normally terminate as well-ordered simple, branched or unbranched free nerve endings (FNE), while A\(\beta\) fibers terminate as site specific, morphologically unique specialized endings [34, 37, 49, 51]. For example, certain small-caliber C fibers terminated among epidermal keratinocytes as intraepidermal nerve fibers (IENF) (curved arrows, Fig 2A–2C). A mix of A\(\beta\) and C fibers terminated as Meissner corpuscles in dermal papillae (broad arrow, Fig 2A) [52] and as tooth-like lanceolate endings around the perimeter of hair follicles (broad arrows, Fig 2D and 2F) [31, 34, 49].

**Aberrant pre-cNF innervation.** Double-label combinations revealed that the aberrant dense innervation in pre-cNF (arrowheads, Figs 2–4), immunolabeled for PGP, had an especially thinner caliber than any small-caliber innervation in biopsies from normal subjects and was negative for MBP, negative for cholinergic, and negative for noradrenergic properties. Relatively little of the aberrant innervation co-labeled for CGRP, indicating that the vast majority of pre-cNF innervation is composed of nonpeptidergic C fibers and their FNE (green arrowheads). Importantly, despite the lack of MBP labeling, a substantial proportion of the innervation did label for NF200, which is not normally expressed in mature unmyelinated C fibers [34, 37, 53]. One possibility for NF200 labeling in pre-cNF may be the presence of unmyelinated branches sprouting from A\(\delta\) or A\(\beta\) fibers (Section B in S1 Text). Alternatively, NF200 is normally upregulated in all types of innervation during development before myelination occurs, but normally only persists in mature A\(\delta\) and A\(\beta\) fibers that become myelinated [53–55]. NF200 also upregulates among all fiber types including C fibers during regeneration [56].

Virtually all of the aberrant pre-cNF innervation also co-labeled with GAP-43 in alternating sections (not shown, but see Fig 7A–7C), which is expressed during normal axon growth, plasticity, regeneration, and pathological sprouting [34, 37, 57]. Like NF200, GAP-43 is expressed in all fiber types during normal development, but unlike NF200, GAP-43 normally downregulates in A\(\delta\) and A\(\beta\) fibers as they mature and stabilize [37, 58]. Unlike in mature myelinated fibers, GAP-43 continues expression in most mature unmyelinated fibers—sympathetic and sensory—indicating normal constant remodeling [34, 37, 59, 60]. Therefore, the NF200 expression among the aberrant, extremely fine caliber fibers of the pre-cNF could be indicative of an
excessive sprouting of nonpeptidergic C fibers and/or de novo unmyelinated sprouting of destabilized Aδ or Aβ fibers.

**Aberrant s-cNF innervation.** As with pre-cNF, virtually all of the innervation in s-cNF was small caliber and co-labeled for PGP and GAP-43 (Figs 7 and 8A–8C). A substantial proportion of the PGP-labeled fibers co-labeled for NF200 (Fig 8D–8F), but lacked MBP (not shown). CGRP was barely detectable among aberrant fibers as compared to normal peptidergic C fibers (Fig 8G–8I). Among the aberrant innervation in s-cNF affiliated with a sweat gland core, very little labeling was found for the cholinergic markers, pChAT and VACHT (not shown). Likewise, little of the aberrant innervation in s-cNF affiliated with arterioles or AVS expressed the noradrenergic markers, DBH or NPY (not shown). Therefore, as observed in the pre-cNF, the vast proportion of the aberrant innervation in s-cNF appears to be highly sprouted nonpeptidergic C fibers, perhaps with some unmyelinated branches of Aδ or Aβ fibers.

Given that PGP and GAP-43 are presumably produced in the sensory neurons in dorsal root ganglia (DRG), and transported anterogradely into the axons and their terminals, mRNA transcripts for GAP-43 were virtually absent in s-cNF although moderate levels for UCHL1 were detected (Fig 9) likely related to observations that low levels of PGP immunolabeling can be detected on nSC [61, 62]. Compared to normal skin, relative levels of transcripts in s-cNF were similar for UCHL1 but significantly higher for GAP-43 (Fig 10). The mRNA analyses of s-cNF revealed a moderate to high levels for ENO2 that was significantly higher than in normal skin (Figs 9 and 10). ENO2 translates to a pan-neuronal enzyme neuron-specific enolase (NSE). However, subsequent s-cNF immunolabeling for NSE revealed a high level expression not only on the aberrant innervation but also the excessive associated nSC (Fig 8C, inset) as reported previously [63].

**Profiling nSC and other non-neuronal cells in pre-cNF and s-cNF**

**nSC immunolabeling.** Labeling for the generic SC marker S100B [31, 33, 64], revealed that virtually all of the aberrant C fibers in pre-cNF and s-cNF were closely affiliated with nSC, and that clusters of nSC could also be present in excess of associated fibers in s-cNF (Figs 5A–5C and 8J–8L). This suggests that in pre-cNF, initial nSC proliferation parallels the sprouting of the aberrant innervation, whereas in s-cNF the nSC begin autonomous clonal proliferation that loses contact with the sprouting innervation.

**SC precursor cells.** Transforming growth factor-beta1 (TGFβ1) has been implicated in promoting SC proliferation and differentiation especially under tumorigenic conditions [65–68]. Therefore, both pre-cNF and s-cNF were immunolabeled for TGFβ1 (Fig 11A–11F). In the pre-cNF, TGFβ1 labeling was observed on focal, densely-packed small cell clusters that did not label for S100B, and were distinct from S100B-labeled presumptive nSC (Fig 11A–11C). In s-cNF, large zones of similar densely packed small TGFβ1-positive, S100B-negative cells were intercalated with, and segregated from zones containing the aberrant innervation and affiliated S100B-positive presumptive nSC (Fig 11D–11F). In pre-cNF and s-cNF, the TGFβ1-positive/S100B-negative cells as well as the S100B-positive/TGFβ1-negative nSC co-labeled for the transcription factor SOX-10 (Fig 11G–11L), an SC developmental lineage marker [69–72], indicating that the TGFβ1-positive/S100B-negative cells were likely proliferating SC precursors [6].

**SC related mRNA detection.** The immunolabeling results in s-cNF were supported by high levels of mRNA transcripts for TGFβ1 and SOX10 in s-cNF from the same and additional NF1 patients, as well as moderate levels for NCAM1 and L1CAM which are other, albeit less specific markers for SC progenitors (Fig 10). Relative levels of all four transcripts were
expressed at especially significant higher levels in the s-cNF as compared to normal skin (Fig 10). Given the numerous S100B immunolabeled nSC in s-cNF, transcripts for S100B were relatively moderate but were especially significant higher levels than in control skin (Figs 9 and 10).

**Unidentified cells.** Given the affiliation between the excessive nSC and aberrantly sprouting innervation, pre-cNF and s-cNF were immunolabeled for neuregulin-1 (NRG-1), a key mitogen implicated in SC proliferation and axon/SC sensory signaling [73, 74]. Pre-cNF contained clusters of small cells that labeled with NRG-1, but not S100B, and were intermingled with the S100B labeled SC (Fig 5D–5F). The clustered NRG-1-positive cells in pre-cNF had few processes, did not resemble fibroblasts, and they did not intimately associate with the aberrant sensory fibers. By contrast, NRG-1 labeling in s-cNF only showed few similar cells which were not as densely packed and did not have the same morphology of those in the pre-cNF that labeled for TGFβ1 (not shown).

**Mast cells, compartmentalizing cells, and sensory corpuscles.** See Section C and Section D in S1 Text and S2 Fig and S3 Fig.

**Potential neural signaling mechanisms between aberrant innervation and nSC**

That the aberrant innervation in pre-cNF and s-cNF was overwhelmingly composed of non-peptidergic C fibers suggested the possible presence of ligands and receptors for two major neurotrophic factor systems that promote outgrowth of C fibers: the nerve growth factor (NGF) family and glial-derived neurotrophic factor (GDNF) family [75–78], (Section E in S1 Text). Of particular relevance to C-fibers, peptidergic C-fibers are dependent upon NGF signaling through the presence of the high affinity TrkA kinase receptor throughout development and continued adult maintenance. By contrast nonpeptidergic C fibers are initially dependent upon NGF/TrkA signaling, then switch to express and depend upon c-Ret [78–81], which is the kinase receptor common to each member of the GDNF family (GDNF, neurturin [NTRN], artemin [ARTN], and Persiphin [PSPN]) that selectively signal through c-Ret via specific co-receptors GFRα1–4, respectively [52, 78–80, 82, 83].

**GDNF family of neurotrophins.** Consistent with ITD-CMA indications that nonpeptidergic C-fiber were source of aberrant terminal sprouting in pre-cNF and s-cNF, immunolabeling for c-Ret was widely expressed not only on the aberrant innervation but also on the excessive nSC in the s-cNF (Fig 12A–12F), whereas immunolabeling for TrkA was inconclusive. Immunolabeling for c-Ret co-receptors in s-cNF failed to reveal GFRα1 and GFRα4, the primary co-receptors for GDNF and PSPN, respectively (Fig 13A–13F). Robust immunolabeling was detected for the NRTN co-receptor GFRα2 on both the aberrant innervation and nSC (Fig 13G–13L), and for the ARTN co-receptor GFRα3 primarily on the aberrant innervation (Fig 13M–13O).

Correspondingly, mRNA transcripts in s-cNF were consistently high for RET and NTRN, moderate to high for GFRα2 and GFRα3, and moderate for ARTN. Transcripts were lower and more variable among s-cNF for GDNF and PSPN, and virtually non-existent for GFRα1 and GFRα4 (Fig 9). In comparison to normal skin, relative levels of transcripts in s-cNF were...
also significantly higher for NRTN, GFRA2, and GFRA3, comparable for RET, but significantly extremely lower for ARTN (Fig 9). GFRA1 was significantly higher in s-cNF than in normal skin, but GDNF, PSPN, and GFRA4 were significantly lower.

**NGF family of neurotrophins.** Consistent for inconclusive TrkA immunolabeling, transcripts for NTRK1 ranged from low to virtually non-existent among s-cNF from different patients and was significantly relatively lower than in normal skin (Figs 9 and 10). Otherwise, among the various ligands and receptors of the NGF family, only NTF4 transcripts were consistently high in s-cNF but its relative levels were significantly lower than in normal skin (Figs 9 and 10).

Transcripts were especially high for NGFR that translate to the low affinity nerve growth factor receptor (NGFR or p75) for all the NGF family ligands. Immunolabeling for NGFR in s-cNF was exceptionally robust, but surprisingly limited almost entirely to an unknown type of S100B negative cells (see Section D in S1 Text and S3 Fig) that seemingly forms partitions within the s-cNF like those described previously as compartmentalizing cells [30].

**Potential functional properties of aberrant s-cNF innervation**

**TrpA1 and TrpV1 detection.** Previous studies demonstrated that ARTN/GFRα3/c-Ret signaling can enhance expression on nonpeptidergic C fibers of the cation channel transient...
receptor potential receptors, TrpA1 and TrpV1, which are implicated in itch and pain mechanisms, respectively [27, 29, 63, 84–89]. Immunolabeling of s-cNF detected extensive TrpA1 among the aberrant innervation (yellow arrowheads, Fig 14A–14C). TrpV1 immunolabeling

Fig 13. Aberrant innervation of s-cNF express co-receptors of GDNF family ligands. s-cNF aberrant innervation expresses immunolabeling for c-Ret co-receptors GFRα2 and GFRα3. A-F: No co-labeling was detected for GFRα1 and GFRα4 on the aberrant innervation labeled for GAP-43 (green arrowheads). G-L: Labeling for GFRα2 was widely co-expressed on or associated with most, but not all GAP-43-labeled aberrant innervation (yellow and green arrowheads). Co-labeling for S100B revealed some GFRα2 on SC as well as the innervation. M-O: GFRα3 is expressed on some, but not all of the GAP-43-labeled innervation (yellow and green arrowheads). GFRα3 was not obviously expressed on SC. Scale bar = 25μm.

https://doi.org/10.1371/journal.pone.0216527.g013
was detected not only on at least some of the innervation but also among the associated SC (yellow and red arrowheads, respectively, Fig 14D–14F). Transcripts were consistently moderate for TrpA1 in s-cNF from different patients but relatively the same as in normal skin. However, consistent with TrpV1 immunolabeling on nSC, transcripts for TRPV1 were consistently high among s-cNF and significantly higher relative transcripts in normal skin. Both TrpA1 and TrpV1 are known to be expressed in epidermal keratinocytes [89, 90], which would also be included among the assayed dissociated s-cNF components.

**Genetically-induced mouse pre-cNF**

Human pNFs and cNF are thought to result from proliferation of SC that have undergone transformation from monoallelic to biallelic mutations of NF1. With our discovery of pre-cNF in humans, we re-investigated the mouse model developed previously by Wu et al., 2008 [21], which had a conditional SC-specific DI Nf1 induced mutation. The original study revealed induced pNFs, but visible cNF were not evident. Consistent with indications that human cNF evolve from pre-cNF, our immunolabeling re-assessment of glabrous and hairy hind paw skin of these conditionally induced SC Nf1⁻/⁻ mice revealed pre-cNF-like pathologies associated with occasional hair follicles, sweat glands, and arterioles in two out of four mice (Fig 15). Consistent with the human pre-cNF, virtually all the excessive innervation lacked immunolabeling for CGRP, indicating it primarily consisted of nonpeptidergic C fibers. Overall, most hair follicles, sweat glands, and segments of arterioles had normal-appearing innervation in the PlpCre; Nf1⁻/⁻ mice indicating that the potential for triggering presumptive pre-cNF is increased but is nonetheless sporadic as in humans.
Discussion

Origin of cNF

The origin of pNF and cNF in NF1 patients has been attributed to an increased probability of aberrant hyperproliferation by nSC due to a nSC-specific spontaneous monoallelic to biallelic loss-of-function mutation of \( \text{NF1} \) resulting in a depletion of neurofibromin. Neurofibromin is normally implicated in a Ras-GTPase inhibitory modulation of several Ras-mediated functions that includes suppression of undesirable cell proliferation [15–18]. As a result of an increased probability for uncontrolled nSC proliferation, pNFs and cNF occur sporadically varying in frequency and size among NF1 patients [1–3, 8, 91, 92]. The NF1 mechanism is distinct from that in NF2 involving the mutation of \( \text{NF2} \), which encodes the ezrin-radixin related protein, merlin, resulting in the development of true schwannomas rather than cNF or pNFs [93, 94]. The trigger for why suspected spontaneous SC biallelic mutations presumably occur and begin to hyperproliferate at random sites causing cNF is unknown [1, 6, 30].
Adnexal pre-cNF as the site of cNF genesis

Although some innervation had been observed previously in cNF [30] and implicated in NF1 DI SC hyperproliferation [95, 96], our ITD-CMA results of our study indicate that the cNF consistently originate among nonpeptidergic C-fiber terminals on adnexal skin structures: hair follicles, sweat glands, sweat ducts, sweat glands, arterioles, and AVS. Under normal conditions, each type of adnexal structure is innervated by structure-specific combinations of sensory and sympathetic terminals that are intimately in contact with terminal nSC [34, 36, 37, 49].

The implication of our ITD-CMA structural and molecular profiling is that each cNF begins in seemingly normal skin at an adnexal structure as a tiny microlesion (pre-cNF) that consists of a focal sprouting of sensory endings of nonpeptidergic C-fibers and a concomitant proliferation of their associated terminal nSC. As such, these aberrant terminals may contribute to chronic pain and itch in NF1 patients [1, 2, 22–25], which can occur in seemingly normal skin before the s-cNF appear. With the presumptive original adnexal structure consistently detected at the core, our ITD-CMA of s-cNF revealed that they have structural properties and neurochemical profiles consistent with a logical genesis from pre-cNF [34, 36, 37, 49] in that the nonpeptidergic C-fiber terminals and their associated nSC continue to sprout and proliferate to form the stalk and cap-like bulk of the emergent s-cNF. Once the process is initiated, the nSC continue to proliferate in excess of the sprouting innervation as the cNF increase in size. Consistent with terminal sprouting, virtually all of the aberrant innervation as revealed by anti-PGP-IL robustly co-expresses GAP43-IL (Section F in S1 Text).

Although molecular properties of innervation can deviate from normal under pathological conditions [32, 34, 53, 97–99], the ITD-CMA profile indicating that the sprouting consisted primarily of nonpeptidergic C-fiber terminals was surprising. Normally the nonpeptidergic C-fibers are just a small contingent among several other varieties of innervation that normally terminate on the various types of adnexal structures. For example, the predominant C-fiber innervation of each type of adnexal structure is peptidergic and normally expresses robust immunolabeling for CGRP, which was, at best, barely detectable among the aberrant innervation in the pre-cNF and s-cNF. Otherwise, additional dense unmyelinated innervation terminates on arterioles and AVS and on sweat glands that consists of noradrenergic and cholinergic sympathetic fibers, respectively, but none of their molecular properties were immunodetectable among the aberrant pre-cNF and s-cNF innervation. Finally, pre-cNF and s-cNF only contain sparse, if any definitive myelinated small-caliber Aδ fibers and large-caliber Aβ fibers that normally contribute some sensory endings on arterioles and AVS and several dense varieties of morphologically unique sensory endings on hair follicles. However, some of the s-cNF contained sparse Aβ fibers that were the source of unusual small, encapsulated endings that had been observed previously in cNF but have not been reported in normal human skin [100] (Section B in S1 Text).

Nonmyelinating terminal SC, SC precursors, and other cell types in pre-cNF and s-cNF

Nonmyelinating SC. S100B labeling and the absence of MBP confirmed the presence of numerous mature SC intimately associated with the aberrant fibers both in pre-cNF and s-cNF. While C fibers and sympathetic fibers within nerves are normally sheathed only by nSC, all endings of sensory and sympathetic fibers are also normally intimately affiliated with specialized nSC, also referred to as terminal glia, regardless of whether the source axons are myelinated or unmyelinated. Within the pre-cNF and s-cNF, nSC at first appear to have proliferated in proportion to the excessive aberrant terminals but, in some s-cNF, there were
locations where clusters of nSC apparently continued to proliferate in excess and independent of associated innervation.

**Potential SC precursors.** Both the pre-cNF and s-cNF contained clusters of cells that were S100B-negative but expressed TGFβ1, which has been implicated in promoting SC proliferation and differentiation especially under tumorigenic conditions [65–67, 88, 101–103]. In the s-cNF, they could be densely packed in zones intercalated with but segregated from zones containing the aberrant innervation and affiliated SC that were S100-positive but TGFβ1-negative. Both the TGFβ1 cells and mature nSC co-labeled for the transcription factor SOX-10, an SC developmental lineage marker [65, 69–72], thus indicating that the TGFβ1 cells were a potential precursor source of the excessive SC [6]. The functional genomics assessment of s-cNF confirmed a high level of message expression for TGFβ1 and SOX-10.

**SKPs and BCCs.** While it is known that SC are one of many cell types that are derived from neural crest cells [104–106], subtypes of SC exist that may have different lineages of differentiation, including from SKPs [107–111] and from BCCs [112–116]. The detection of SKPs to date has been limited primarily to the base of hair and whisker follicles in mice, which are sites that have little if any innervation and were not sites where pre-cNF were detected in NF1 patients.

By contrast, a line of mice that expresses a BCC-driven reporter gene revealed that BCC-derived nSC originate from BCCs located at the attachments of developing nerve roots to the spinal cord during early embryogenesis. BCC-derived SC migrate to developing nerve plexuses where pNFs evolve in NF1 patients, as well as through developing nerves to become terminal nSC in the skin where the pre-cNF are located [116]. Consistent with this observation, pNF were detected in our original assessment of an SC selective Nf1 DI mouse model developed in 2008 [21]. Our reassessment, herein, revealed pre-cNF-like lesions in the skin of these mice that were located at various adnexa where the pre-cNF were discovered in our human NF1 patients. A recently developed BCC selective Nf1 DI mouse model produced more obvious human-like cNF as well as pNFs [117]. This suggests that the hyperproliferating SC and likely TGFβ1-positive SC precursors in the pre-cNF and s-cNF in our NF1 patients arise de novo exclusively among the BCC-derived terminal SC. Whether or not they are Nf1 DI remains to be determined.

Despite having different timings in their develop and potential to become malignant, an intriguing possibility is that the hyperproliferating SC in pNFs may also be a type of nonmyelinating terminal SC given that both pNFs and cNF have similar histological and functional genomics profiles and both may be derived from BCC lineages. In this case, the SC hyperproliferation in pNFs may involve terminal SC affiliated with arterioles within nerve plexuses that also have innervation, referred to as the nervi nervorum, like that of cutaneous arterioles [36, 118–121].

**NGFR expressing “compartmentalizing” cells.** Our ITD-CMA of the s-cNF failed to detect labeling for NGFR on the excessive nSC, as has been reported previously, despite high levels of NGFR message in the cNF. However, NGFR immunolabeling was intensely expressed among cells that were negative for S100B but seemed to form partitions among the aberrant innervation and excessive SC. Similar cells were described as compartmentalizing cells in a previous study. A definitive identity of these cells was not ascertained but may indicate a transition into another form of SC that may begin to infiltrate and become dominant in the further evolution of cNF.

**Mast cells.** Mast cells have been identified as a substantial contributor to cNF, possibly as a source of itch symptoms [27–29, 122]. Our histochemical assessment revealed more numerous but still relatively sparse distributions of mast cells in both the pre-cNF and s-cNF as compared to normal skin. Consequently, our impression is that mast cells and associated inflammatory mechanisms may be relatively minor factors in the initiation and early development of cNF [103], but may become more significant in later stages of cNF enlargement.
Potential trophic mechanisms involved in the onset of pre-cNF and evolution into cNF

**NTRN and ARTN signaling.** Consistent with ITD-CMA indications that the aberrant innervation in pre-cNF and s-cNF consists primarily of terminals of nonpeptidergic C fibers, both the ITD-CMA and functional genomic analyses of the s-cNF indicated that NTRN and ARTN signaling mechanisms involving GFRα2 and GFRα3 may be interacting between the aberrant C-fiber terminals and associated nSC in initiating the pre-cNF and facilitating their evolution into s-cNF [86, 87].

The aberrant nonpeptidergic C fiber innervation in the s-cNF robustly immunolabeled for c-Ret and was inconclusive for TrkA. Additional immunolabeling combinations demonstrated co-labeling for the c-Ret co-receptor GFRα3 and likely some GFRα2, whose preferential signaling ligands are ARTN and NTRN, respectively. Both of these NTs are known modulators of primary afferent innervation and function [85, 88, 123]. Virtually no immunolabeling of the aberrant innervation was detected for GFRα1 and GFRα4, whose preferential signaling ligands are GDNF and PSPN, respectively.

Interestingly, the excessive associated nSC also robustly immunolabeled with c-Ret [124, 125], GFRα2, and perhaps some GFRα3, indicative of potential autocrine/paracrine signaling between the SC and between the aberrant innervation and SC [126–129]. Functional genomics assessments verified a consistently high level of RET and NTRN transcripts among s-cNF from different NF1 patients, as well as moderate to high levels for GFRA2, GFRA3, and ARTN. Compared to normal skin, relative transcripts for NTRN, GFRA2, and GFRA3 were significantly higher in s-cNF whereas c-Ret was similar. Surprisingly, transcripts for ARTN were significantly lower in the cNF as compared to normal skin. Whereas Friedrich et al., 2016 ([30]) reported single immunolabeling for GDNF and GFRα1 as well as TrkA in cNF, our analyses detected little or was inconsistent for these or any of the ligands or other high affinity receptors at least among s-cNF.

Taken together, our results indicate that NTRN and ATRN signaling interactions between the C fiber terminals and their terminal SC, as well as autocrine/paracrine signaling among the SC, contribute to the initiation of pre-cNF and subsequent evolution into overt cNF. Consistent with a mutual interaction between the innervation and nSC in the onset and development of s-cNF, one report indicated that denervation of NF1 skin could reduce the number and size of cNF [130].

**TrpA1 and TrpV1.** Consistent with a known impact of ARTN and NTRN signaling on C fiber sensory neurons, the aberrant nonpeptidergic innervation in the s-cNF expressed immunolabeling for TrpA1 and TrpV1, which have previously been implicated in itch and pain mechanisms [29, 84, 86, 87, 89, 131–134]. As has been seen on other non-neuronal cells [89, 135], TrpV1 immunolabeling, supported by mRNA transcripts, was also detected on the excessive nSC in s-cNF, which had not been reported previously on normal SC. Therefore, the expression of TrpA1 and TrpV1 on the aberrant innervation and even TrpV1 on the excessive nSC in s-cNF may contribute to symptoms of itch and pain in NF1 patients.

**What triggers the onset of pre-cNF and the evolution of cNF?** Our observations indicate that there is something about the nonpeptidergic C fiber terminals and their associated SC at a variety of adnexa that increases the probability of triggering a pre-cNF and their subsequent likely evolution into overt cNF. Strong evidence indicates that an NF1-/- transformation of SC is key to their hyperproliferation and genesis of all types of NF1 neurofibromas. Conditionally induced Nf1 DI selectively in SC or BCCs of mice also produce neurofibromas within nerve plexuses and nerves as well as pre-cNF-like lesions in the skin, that seem to evolve into overt cNF in the BCCs of Nf1 DI mice.
However, the various neurofibromas occur in Nf1 DI mouse models in relatively few sites where mutated SC and BCCs are located. Likewise, while pre-cNF and s-cNF in NF1 patients apparently originate only among various types of cutaneous adnexal structures, they occur among relatively few of all possible adnexae even in patients with numerous cNF. Therefore, while Nf1 DI transformations increase the probability that neurofibromas will occur, the mechanism(s) that actually triggers pNFs and cNF remains unknown.

Despite the considerable quantity of excessive innervation in the s-cNF, the likely origin from a small subset of sensory fibers associated with a specific adnexa suggests that relatively few DRG neurons may account for the excessive sprouting in each cNF. The capacity for excessive sprouting by C fibers has been shown in transgenic mouse lines designed to overproduce various neurotrophic factors in keratinocytes [76, 136].

Our observations indicate that the trigger for the occurrence of a pre-cNF and potential subsequent evolution into a cNF involves a local trophic interaction between nonpeptidergic C-fiber endings and their associated terminal SC at any type of adnexa that is a normal site where these endings are located. Moreover, the trophic interaction may involve ARTN- and/or NRTN- signaling through c-Ret expressed on both the nonpeptidergic C fibers and terminal SC. Whereas C fibers are typically regarded as nociceptors involved in pain sensation, there is increasing evidence that many, if not most, are normally involved in local homeostatic monitoring and maintenance of target structures.

The normal expression of GAP-43 among C fibers may be indicative of an ongoing remodeling of their sensory endings and associated terminal glia as part of a normal homeostatic monitoring subliminal maintenance which regularly fluctuates in response to transient tissue stressors, becoming especially exaggerated as part of wound repair [29, 35, 49, 113, 121, 137–141]. As such, the Nf1 germinat mutation may compromise the neural/SC cooperativity involved in normal tissue homeostasis. Nf1 DI may arise subsequently in an inappropriately mitotically active SC population [17]. Possibly, the adnexae themselves may exert some degree of paracrine tropism, specifically attracting critical cells from already-established NFs or other sites. Others have proposed possible seeding from mature neurofibromas and the existence of precursor lesions involving a specific neurofibroma precursor cell [8, 142]. Comparable to the Nf1 pre-cNF, hamartia are microscopic lesions well-documented in the Tuberous Sclerosis Complex that precede and evolve into hamartomas [10].

**Conclusion**

Our observations on the pre-cNF and s-cNF indicate that cNF are not initiated simply by autonomous clonal proliferations of SC or SC precursors that have undergone an Nf1−/− transformation. Rather, they appear to involve an initial trophic interaction between cutaneous C fiber sensory endings and their terminal SC associated with skin adnexae that may involve ARTN and NTRN signaling through c-Ret receptors on both the innervation and SC. This suggests that the pre-cNF and the evolution to cNF may arise on the basis of dysplasia [13] and not simply neoplasia in accordance with the canonical two-hit model. As such, therapeutic strategies that target the c-Ret signaling mechanism at the earliest appearance of a s-cNF may prevent the further development or maintenance of the cNF.

**Supporting information**

S1 Text. Supplemental text. (DOCX)
S1 Fig. Secondary antibody labeling and autofluorescence. Secondary antibodies produced no detectable labeling above background autofluorescence in s-cNF. Example pairs of secondary antibody fluorescence in the absence of primary antibodies (A-E) as compared to autofluorescence (F). Note the autofluorescence of vascular profiles likely due to the presence of albumen (arrowheads). Scale bar = 50 μm.

(TIF)

S2 Fig. Mast cells (MC). Toluidine blue labeling revealed scattered, seemingly uniform distributions of MCs (arrowheads) in both a pre-cNF (A) and a s-cNF (B). Staining revealed MCs abnormally numerous and diffusely distributed throughout s-cNF (S2B Fig) as was known previously [19, 26, 63, 122]. Likewise, mast cells were diffusely distributed within the pre-cNF at a higher density than the surrounding dermis (S2A Fig). MC density was far less than that of TGFβ1 and of NRG-1 immunolabeled cells that also had a different morphology. Scale bar = 25 μm.

(TIF)

S3 Fig. Compartmentalizing Cells and Sensory Corpuscles. In s-cNF, NGFR immunolabeled cells (A-C, G-I; curved red arrows) have processes that form partitions among the aberrant innervation labeled for PGP (A-C, green arrowheads) and the accompanying S100B-labeled SC (G-I, curved green arrows and arrowheads). Some NGFR-positive cells appear to form enclosures (broad red arrows, A-C and G-I) of encapsulated large-caliber sensory endings that label for PGP (broad green arrows, A-C) and NF200 (broad yellow arrows, D-F). The matrix within the capsule and surrounding the ending labels with S100B and MBP (D-I). These are likely endings supplied by sparse large-caliber myelinated Aβ fibers that label for NF200 and MBP (large green arrows with red borders, D-F). Smaller-caliber lightly myelinated Aδ fibers are also present (small green arrows with red borders, D-F) seen losing their myelin sheath as it may be terminating (small green arrow). Note a capsule (broad red arrows) that contain a PGP-labeled large-caliber axon at the core (open yellow arrowheads). Relatively large-caliber axons also label for NGFR (solid yellow arrowheads, A-C) whereas the aberrant small-caliber axons lack NGFR (green arrowheads, A, B). Scale bar = 25 μm.

(TIF)

Acknowledgments

We wish to thank Pamela Knight of the Children’s Tumor Foundation for providing the s-cNF, and Drs. Katherine Albers, Brian Davis, Freda Miller, Sally Temple, David Ginty, and Derek Molliver for their suggestions and insights on the study design, data interpretation, and manuscript.

Author Contributions

Conceptualization: Frank L. Rice, James P. Wymer, Sara J. C. Gosline, Steven L. Carroll, Phillip J. Albrecht, Vincent M. Riccardi.

Data curation: Frank L. Rice, George Houk, James P. Wymer, Sara J. C. Gosline, Justin Guinney, Marilyn Dockum.

Formal analysis: Frank L. Rice, George Houk, James P. Wymer, Sara J. C. Gosline, Justin Guinney, Steven L. Carroll, Vincent M. Riccardi.

Funding acquisition: Frank L. Rice, James P. Wymer, Nancy Ratner.

Investigation: Frank L. Rice, Sara J. C. Gosline, Justin Guinney, Jianqiang Wu, Salvo La Rosa.
Methodology: Frank L. Rice, James P. Wymer, Sara J. C. Gosline, Jianqiang Wu, Nancy Ratner, Michael P. Jankowski, Marilyn Dockum, James R. Storey, Phillip J. Albrecht.

Project administration: Frank L. Rice, James P. Wymer.

Resources: Frank L. Rice, James P. Wymer, Sara J. C. Gosline, Jianqiang Wu, Nancy Ratner, Salvo La Rosa.

Software: Sara J. C. Gosline.

Supervision: Frank L. Rice, James P. Wymer.

Validation: Frank L. Rice, Sara J. C. Gosline, Nancy Ratner, Michael P. Jankowski, Steven L. Carroll, Phillip J. Albrecht, Vincent M. Riccardi.

Visualization: Frank L. Rice.

Writing – original draft: Frank L. Rice, Vincent M. Riccardi.

Writing – review & editing: Frank L. Rice, George Houk, James P. Wymer, Sara J. C. Gosline, Nancy Ratner, Michael P. Jankowski, Salvo La Rosa, Steven L. Carroll, Phillip J. Albrecht, Vincent M. Riccardi.

References

1. Longo JF, Weber SM, Turner-Ivey BP, Carroll SL. Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. Adv Anat Pathol. 2018. Epub 2018/05/16. https://doi.org/10.1097/PAP.0000000000000197 PMID: 29762158.

2. Riccardi VM. Neurofibromatosis: Phenotype, Natural History and Pathogenesis. Baltimore: Johns Hopkins University Press; 1992. 1–498 p.

3. Riccardi VM. Translational Genetics and Genomics: The Fundamental Nature of NF1 Neurofibromas. JTranslGenet Genom. 2017; 1(1):1–12. Epub 2/123/2017.

4. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007; 26(32):4609–16. Epub 2007/02/14. 1210261 [pii] https://doi.org/10.1038/sj.onc.1210261 PMID: 17297459; PubMed Central PMCID: PMC2760340.

5. Tucker T, Riccardi VM, Brown C, Fee J, Sutcliffe M, Velikind J, et al. S100B and neurofibromin immunostaining and X-inactivation patterns of laser microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas. Journal of Neuroscience Research. 2011; 89:1451–60. https://doi.org/10.1002/jnr.22654 PMID: 21674567

6. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia. 2008; 56 (14):1590–605. Epub 2008/09/23. https://doi.org/10.1002/glia.20776 PMID: 18803326; PubMed Central PMCID: PMC2652636.

7. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009; 1 (4):236–48. Epub 2010/01/06. https://doi.org/10.1002/emmm.200900027 PMID: 20049725; PubMed Central PMCID: PMC3378132.

8. Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, et al. The development of cutaneous neurofibromas. Am J Pathol. 2011; 178:500–5.

9. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoeti ology of neurofibromatosis 1. Am J Pathol. 2011; 178(5):1932–9. Epub 2011/04/05. https://doi.org/10.1016/j.ajpath.2010.12.056(11)00172-6 [pii]. PMID: 21457932; PubMed Central PMCID: PMC3081157.

10. Darling TN. Hitting the mark in hamartoma syndromes. Adv Dermatol. 2006; 22:181–200. Epub 2007/01/26. PMID: 17249302.

11. Riccardi VM. Histogenesis control genes: embryology, wound healing and NF1 (Letter to the Editor). Teratology. 2000; 62:4–5. https://doi.org/10.1046/j.1096-9926(200007)62:1-4:AID-TERA2.0.CO;2-Q PMID: 10861625

12. Riccardi VM. The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. NeurosurgFocus. 2007; 22(6):E3:1–11.

13. Riccardi VM. Neurofibromatosis type 1 is a disorder of dysplasia: The importance of distinguishing features, consequences, and complications. Birth Defects ResA Clin Mol Teratol. 2010; 88:9–14.
14. Carroll SL, Stonecipher MS. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. J Neuropathol Exp Neurol. 2005; 64(1):1–9. Epub 2005/02/18. PMID: 15715079.

15. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 1995; 11(1):90–2. Epub 1995/09/01. https://doi.org/10.1038/ng0995-90 PMID: 7550323.

16. Kluwe L, Friedrich RE, Mautner VF. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet. 1999; 113(1):65–9. Epub 1999/08/25. PMID: 10459349.

17. Serra E, Rosenbaum T, Nadal M, Winner U, Ars E, Estivill X, et al. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat Genet. 2001; 28(3):294–6. Epub 2001/06/30. https://doi.org/10.1038/90148 PMID: 11431704.

18. Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet. 2000; 9(20):3055–64. Epub 2000/12/15. PMID: 11115850.

19. Yang FC, Ingram DA, Chen S, Hingtgen CM, Hingtgen CM, Ratner N, Monk KR, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1+/- mast cells. J Clin Invest. 2003; 112(12):1851–61. Epub 2003/12/18. https://doi.org/10.1172/JCI19195 [pii]. PMID: 14679180; PubMed Central PMCID: PMC296994.

20. Zheng H, Chang L, Patel N, Yang J, Burns DK, Patel N, Yang J, Meijer D, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell. 2008; 13(2):117–28. Epub 2008/02/05. https://doi.org/10.1016/j.ccr.2008.01.002 [pii]. PMID: 18242512.

21. Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, et al. Plexiform and dermal neurofibromas and pigmentations are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008; 13(2):105–16. Epub 2008/02/05. https://doi.org/10.1016/j.ccr.2007.12.027 [pii]. PMID: 18242511; PubMed Central PMCID: PMC2846699.

22. Brenna E, Nizery-Guermeur C, Audebert-Bellanger S, Ferkal S, Wolkenstein P, Misery L, et al. Clinical Characteristics of Pruritus in Neurofibromatosis 1. Acta Derm Venereol. 2016; 96(3):398–9. Epub 2015/09/10. https://doi.org/10.2340/00015555-2241 PMID: 26349448.

23. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain. 1999; 122 (Pt 3):473–81. Epub 1999/03/27. PMID: 10094256.

24. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Lepelea A. Quality-of-life impairment in neurofibromatosis type 1: a cross- sectional study of 128 cases. Archives of Dermatology. 2001; 137(11):1421–5. PMID: 11708944.

25. Drouet A, Wolkenstein P, Lefaucheur JP, Pinson S, Combenchale P, Gherardi RK, et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain. 2004; 127(Pt 9):1993–2009. Epub 2004/08/10. https://doi.org/10.1093/brain/awh234 [pii]. PMID: 15289270.

26. Tucker T, Riccardi VM, Sutcliffe M, Vleklind J, Wechsler J, Wolkenstein P, et al. Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1. J Histochem Cytochem. 2011; 59(6):584–90. Epub 2011/04/29. https://doi.org/10.1369/0022155411407340 [pii]. PMID: 21525187; PubMed Central PMCID: PMC3201189.

27. Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018; 40(3):249–59. Epub 2018/05/02. https://doi.org/10.1007/s00281-018-0675-z [pii]. PMID: 29713744.

28. O’Brien DE, Brenner DS, Gutmann DH, Gereau RW. Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. J Pain. 2013; 14(6):628–37. Epub 2013/04/13. https://doi.org/10.1016/j.jpain.2013.01.770 [pii]. PMID: 23578956; PubMed Central PMCID: PMC3672240.

29. Akiyama T, Carstens E. Spinal Coding of Itch and Pain. 2014. Epub 2014/05/16. NBK200915 [book accession]. PMID: 24830023.

30. Friedrich RE, Holstein AF, Middendorff R, Davidoff MS. Vascular wall cells contribute to tumorigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study. Anticancer Res. 2012; 32(5):2139–58. Epub 2012/05/18. 32(5):2139 [pii]. PMID: 22593502.

31. Fundin BT, Arvidsson J, Aldskogius H, Johansson O, Rice SN, Rice FL. Comprehensive immunofluorescence and lectin binding analysis of interstitial fur innervation in the mystacial pad of the rat. J Comp Neurol. 1997; 385(2):185–206. Epub 1997/08/25. https://doi.org/10.1002/(SICI)1096-9861(19970825)385:2<185:AID-CNE2>3.0.CO;2-Y [pii]. PMID: 9288123.

32. Petersen KL, Rice FL, Suess F, Bern M, Rowbotham MC. Relief of post-herpetic neuralgia by surgical removal of painful skin. Pain. 2002; 98(1–2):119–26. Epub 2002/07/06. S030439902000295 [pii]. PMID: 12098623.
33. Rice FL, Fundin BT, Arvidsson J, Aldskogius H, Johansson O. Comprehensive immunofluorescence and lectin binding analysis of vibrissal follicle sinus complex innervation in the mystacial pad of the rat. J Comp Neurol. 1997; 385(2):149–84. Epub 1997/08/25. https://doi.org/10.1002/(SICI)1096-9861(19970825)385:2<149::AID-CNE1>3.0.CO;2-1 [pii]. PMID: 9268122.

34. Albrecht PJ, Hines S, Eisenberg E, Pud D, Finlay DR, Connolly MK, et al. Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain. 2006; 120(3):244–66. https://doi.org/10.1016/j.pain.2005.10.035 PMID: 16427199.

35. Albrecht PJ, Hou Q, Argoff CE, Storey JR, Wymer JP, Rice FL. Excessive peptidergic sensory innervation of cutaneous arterio-venule shunts (AVS) in the palmar glabrous skin of fibromyalgia patients: implications for widespread deep tissue pain and fatigue. Pain Med. 2013; 14(6):895–915. Epub 2013/05/23. https://doi.org/10.1111/pme.12139 PMID: 23691965.

36. Bowsher D, Geoffrey Woods C, Nicholas AK, Carvalho OM, Haggett CE, Tedman B, et al. Absence of pain with hyperhidrosis: a new syndrome where vascular affereents may mediate cutaneous sensation. Pain. 2009; 147(1–3):287–98. Epub 2009/10/20. https://doi.org/10.1016/j.pain.2009.09.007 [pii]. PMID: 19836135.

37. Pare M, Albrecht PJ, Noto CJ, Bodkin NL, Pittenger GL, Schreyer DJ, et al. Differential hypertrophy and atrophy among all types of cutaneous nerve fibers in the glabrous skin of the monkey hand during aging and naturally occurring type 2 diabetes. J Comp Neurol. 2007; 501(4):543–67. https://doi.org/10.1002/cne.21262 PMID: 17287131.

38. Barohn RJ. Intraepidermal nerve fiber assessment: a new window on peripheral neuropathy. Arch Neurol. 1998; 55(12):1505–6. Epub 1998/12/29. PMID: 9865792.

39. Lauria G, Lombardi R, Camozzi F, Devigili G. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology. 2009; 54(3):273–85. Epub 2008/07/22. HIS3096 [pii] https://doi.org/10.1111/j.1365-2559.2008.03096.x PMID: 18637969.

40. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008; 110(5):351–62. Epub 2008/04/04. S0001-2409(07)00155-9 [pii] https://doi.org/10.1016/j.acthis.2007.12.004 PMID: 19394843; PubMed Central PMCID: PMC2561960.

41. Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, Gott R. Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain. 2006; 120(3):235–43. Epub 2006/01/24. S0304-3959(05)00604-4 [pii] https://doi.org/10.1016/j.pain.2005.09.036 PMID: 16427737.

42. Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, et al. Keratinocyte expression of calcitonin gene-related peptide beta: implications for neuropathic and inflammatory pain mechanisms. Pain. 2011; 152(9):2036–51. Epub 2011/06/07. https://doi.org/10.1016/j.pain.2011.04.033 PMID: 21641113; PubMed Central PMCID: PMCPMC3157543.

43. Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, et al. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain. 2008; 139(1):90–105. Epub 2008/04/30. https://doi.org/10.1016/j.pain.2008.03.016 PMID: 18442883.

44. Guslin SJ, Weinberg H, Knight P, Yu T, Guo X, Prasad N, et al. A high-throughput molecular data resource for cutaneous neurofibromas. Sci Data. 2017; 4:170045. Epub 2017/04/12. https://doi.org/10.1038/sdata.2017.45 [pii] PMID: 28398289; PubMed Central PMCID: PMC5387919.

45. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. Epub 2015/01/10. https://doi.org/10.1093/nar/gkv007 PMID: 25605792; PubMed Central PMCID: PMCPMC43402510.

46. Jaegle M, Ghazvini M, Mamedeakers W, Piirsoo M, Driegen S, Levavasseur F, et al. The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev. 2003; 17(11):1380–91. Epub 2003/06/05. https://doi.org/10.1101/gad.258203 PMID: 12782656; PubMed Central PMCID: PMCPMC196070.

47. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002; 296(5569):920–2. Epub 2002/05/04. https://doi.org/10.1126/science.1068452 [pii]; PMID: 11988578; PubMed Central PMCID: PMC3024710.

48. Petersen KL, Rice FL, Farhadi M, Reda H, Rowbotham MC. Natural history of cutaneous innervation following herpes zoster. Pain. 2010; 150(1):75–82. Epub 2010/05/12. S0304-3959(10)00208-3 [pii] https://doi.org/10.1016/j.pain.2010.04.002 PMID: 20457490.

49. Rice FL, Albrecht PJ. Cutaneous Mechanisms of Tactile Perception: Morphological and Chemical Organization of the Innervation to the Skin. In: Basbaum AI, Kaneko A, Shepard GM, Westheimer G, editors. Somatosensation. The Senses: A comprehensive Reference 6. San Diego: Academic Press; 2008. p. 1–32.

https://doi.org/10.1371/journal.pone.0216527
50. Fundin BT, Pfaller K, Rice FL. Different distributions of the sensory and autonomic innervation among the microvasculature of the rat mystacial pad. J Comp Neurol. 1997; 389(4):545–68. Epub 1998/01/08. https://doi.org/10.1002/(SICI)1096-9861(19971229)389:4<545::AID-CNE1>3.0.CO;2-0 [pii]. PMID: 9421138.

51. Albrecht PJ, Rice FL. Role of small-fiber afferents in pain mechanisms with implications on diagnosis and treatment. Curr Pain Headache Rep. 2010; 14(3):179–88. Epub 2010/04/29. https://doi.org/10.1007/s11916-010-0105-y PMID: 20425194.

52. Neet KE, Campenot RB. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell Mol Life Sci. 2001; 58(8):1021–35. Epub 2001/09/01. https://doi.org/10.1007/PL00000917 [pii] PMID: 11529495.

53. Carriel V, Garzon I, Campos A, Cornelissen M, Alaminos M. Differential expression of GAP-43 and neurofilament during peripheral nerve regeneration through bio-artificial conduits. J Tissue Eng Regen Med. 2017; 11(2):553–63. Epub 2014/08/02. https://doi.org/10.1002/term.1499 PMID: 25080900.

54. Boumil E, Vohnoutka R, Lee S, Shearer SS. TGFbeta1 modulates the phenotype of Schwann cells at the transcriptional level. Mol Cell Neurosci. 2002; 19(3):307–19. Epub 2002/03/22. https://doi.org/10.1006/mcne.2001.1094 [pii]. PMID: 11906205.

55. Fantini F, Johansson O. Expression of growth-associated protein 43 and nerve growth factor receptor in human skin: a comparative immunohistochemical investigation. J Invest Dermatol. 1992; 99(6):734–42. Epub 1992/12/02. S0022-202X(92)90628-H [pii]. PMID: 1281863.

56. Verze L, Paraninfo A, Viglietti-Panzica C, Panzica GC, Ramieri G. Expression of neuropeptides and growth-associated protein 43 (GAP-43) in cutaneous and mucosal nerve structures of the adult rat lower lip after mental nerve section. J Comp Neurol. 2003; 451(1):35–44. Epub 2003/02/25. S0022-202X(03)00067-7 [pii] https://doi.org/10.1002/jcn.10233 PMID: 12597125.

57. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997; 20(2):84–91. Epub 1997/02/01. S0166-2236(96)10072-2 [pii]. PMID: 9023877.

58. Fantini F, Johansson O. Expression of growth-associated protein 43 and nerve growth factor receptor in human skin: a comparative immunohistochemical investigation. J Invest Dermatol. 1992; 99(6):734–42. Epub 1992/12/02. S0022-202X(92)90628-H [pii]. PMID: 1281863.

59. Verze L, Paranino A, Viglietti-Panzica C, Panzica GC, Ramieri G. Expression of neuropeptides and growth-associated protein 43 (GAP-43) in cutaneous and mucosal nerve structures of the adult rat lower lip after mental nerve section. J Comp Neurol. 2003; 451(1):35–44. Epub 2003/02/25. S0022-202X(03)00067-7 [pii] https://doi.org/10.1002/jcn.10233 PMID: 12597125.

60. Rice FL, Kinnman E, Alsdokgiris H, Johansson O, Arvidsson J. The innervation of the mystacial pad of the adult human hand. Anat Rec A Discov Mol Cell Evol Biol. 2003; 272(1):467–73. Epub 2003/04/22. https://doi.org/10.1002/ar.a.10056 PMID: 12704705.

61. Rice FL, Kinnman E, Alsdokgiris H, Johansson O, Arvidsson J. The innervation of the mystacial pad of the rat as revealed by PGP 9.5 immunofluorescence. J Comp Neurol. 1993; 337(2):366–85. Epub 1993/11/15. https://doi.org/10.1002/cne.903370203 PMID: 8282848.

62. Wang L, Hilliges M, Jernberg T, Wiegled-Edstrom D, Johansson O. Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res. 1990; 261(1):25–33. Epub 1990/07/01. PMID: 2143435.

63. Baratelli F, Le M, Gershman GB, French SW. Do mast cells play a pathogenetic role in neurofibromatosis type 1 and ulcerative colitis? Exp Mol Pathol. 2014; 96(2):230–4. Epub 2014/03/04. https://doi.org/10.1016/j.yexmp.2014.02.006 [pii]. PMID: 24583366.

64. Albuere M, Lopez S, Naves FJ, Martinez-Almagro A, Represa J, Vega JA. S100alpha and S100beta proteins in human cutaneous sensory corpuscles: effects of nerve and spinal cord injury. Annt Reg. 1998; 251(3):351–9. Epub 1998/07/21. https://doi.org/10.1002/(SICI)1097-0185(199807)251:3<351::AID-AP111>3.0.CO;2-N [pii]. PMID: 9669763.

65. Awatramani R, Shumas S, Kamholz J, Scherer SS. TGFbeta1 modulates the phenotype of Schwann cells at the transcriptional level. Mol Cell Neurosci. 2002; 19(3):307–19. Epub 2002/03/22. https://doi.org/10.1006/mcne.2001.1094 [pii]. PMID: 11906205.

66. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006; 25(3):435–57. Epub 2006/09/05. https://doi.org/10.1007/s10555-006-9006-2 PMID: 16951986.

67. Kadono T, Soma Y, Takekara K, Nakagawa H, Ishibashi Y, Kikuchi K. The growth regulation of neurofibroma cells in neurofibromatosis type-1: increased responses to PDGF-BB and TGF-beta 1. Biochem Biophys Res Commun. 1994; 198(3):827–34. Epub 1994/02/15. S0006-291X(84)71118-1 [pii] https://doi.org/10.1016/0006-291X(94)91118-1 PMID: 8117287.

68. Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, et al. In vivo regulation of TGF-beta by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res. 2012; 72(20):5317–27. Epub 2012/06/05. https://doi.org/10.1158/0008-5472.CAN-12-1148 PMID: 22717224.
Bremer M, Froh F, Kichko T, Reeh P, Tamir ER, Suter U, et al. Sox10 is required for Schwann-cell homeostasis and myelin maintenance in the adult peripheral nerve. Glia. 2011; 59(7):1022–32. Epub 2011/04/15. https://doi.org/10.1002/glia.21173 PMID: 21491499.

Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008; 32(9):1291–8. Epub 2008/07/19. https://doi.org/10.1097/PAS.0b013e3181658c14 PMID: 18636017.

Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001; 15(1):66–78. Epub 2001/01/13. https://doi.org/10.1101/gad.186601 PMID: 11156606; PubMed Central PMCID: PMC312607.

Wong CE, Paratore C, Dours-Zimmermann MT, Rochat A, Pietri T, Suter U, et al. Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell BioL 2006; 175(6):1005–15. Epub 2006/12/13. jcb.200606062 pii https://doi.org/10.1083/jcb.200606062 PMID: 17158956; PubMed Central PMCID: PMC2064709.

Stoenceypher MS, Byer SJ, Grizzle WE, Carroll SL. Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene. 2005; 24(36):5589–605. Epub 2005/05/18. 1208730 [pii] https://doi.org/10.1038/sj.onc.1208730 PMID: 15897877.

Fricker FR, Zhu N, Tsoutsoulas C, Abrahamsen B, Nassar MA, Thakur M, et al. Sensory axon-derived neuregulin-1 is required for axoglial signaling and normal sensory function but not for long-term axon maintenance. J Neurosci. 2009; 29(24):7667–78. Epub 2009/06/19. https://doi.org/10.1523/JNEUROSCI.6053-08.2009 PMID: 19535578; PubMed Central PMCID: PMC2875847.

Markus A, Patel TD, Snider WD. Neurotrophic factors and axonal growth. Curr Opin Neurobiol. 2002; 12(5):523–31. Epub 2002/10/09. S0959438802003720 [pii] PMID: 12367631.

Rice FL, Albers KM, Davis BM, Silos-Santiago I, Wilkinson GA, LeMaster AM, et al. Differential dependency of unmyelinated and A delta epidermal and upper dermal innervation on neurotransphins, trk receptors, and p75LNGFR. Dev Biol. 1998; 198(1):57–81. Epub 1998/06/26. S0012160698868133 [pii] PMID: 9640332.

Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001; 11(3):272–80. Epub 2001/06/12. S0959-4388(00)00208-7 [pii] PMID: 11399424.

Balogh RH, Enomoto H, Johnson EM Jr., Milbrandt J. The GDNF family ligands and receptors—implications for neural development. Curr Opin Neurobiol. 2000; 10(1):103–10. Epub 2000/02/19. S0959-4388(99)00048-3 [pii] PMID: 10679429.

Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002; 3(5):383–94. Epub 2002/05/04. https://doi.org/10.1038/nrn812 [pii]. PMID: 11988777.

Fundin BT, Mikaela A, Westphal H, Ernfors P. A rapid and dynamic regulation of GDNF-family ligands and receptors correlate with the developmental dependency of cutaneous sensory innervation. Development. 1999; 126(12):2597–610. Epub 1999/05/20. PMID: 10331972.

Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, et al. IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron. 1997; 19(4):849–61. Epub 1997/11/14. S0896-6273(00)09666-6 [pii]. PMID: 9354331.

Milbrandt J, de Sauvage FJ, Fahmer TJ, Baloh RH, Leitner ML, Tansey MG, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron. 1998; 20(2):245–53. Epub 1998/03/10. S0896-6273(00)00453-5 [pii] PMID: 9491986.

Wang X. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET. Biochim Biophys Acta. 2013; 1834(10):2205–12. Epub 2012/10/23. https://doi.org/10.1016/j.bbabap.2012.10.008 [pii] PMID: 23085183.

Moore C, Gupta R, Jodli SE, Chen Y, Liedtke WB. Regulation of Pain and Itch by TRP Channels. Neurosci Bull. 2018; 34(1):120–42. Epub 2017/12/29. https://doi.org/10.1007/s12264-017-0200-8 [pii] PMID: 29282613; PubMed Central PMCID: PMC5799130.

Ellitt CM, McIvor SL, Lawson JJ, Malin SA, Molliver DC, Cornuet PK, et al. Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J Neurosci. 2006; 26(33):8578–87. Epub 2006/08/19. 26/33/8578 [pii] https://doi.org/10.1523/JNEUROSCI.2185-06.2006 PMID: 16914684.

Ikeda-Miyagawa Y, Kobayashi K, Yamanaka H, Okubo M, Wang S, Dai Y, et al. Peripherally increased artemin is a key regulator of TRPA1/V1 expression in primary afferent neurons. Mol Pain. 2015; 11:8. Epub 2015/04/19. https://doi.org/10.1186/s12990-015-0004-7 [pii] PMID: 25889193; PubMed Central PMCID: PMC4357199.
87. Ito K, Enomoto H. Retrograde transport of neurotrophic factor signaling: implications in neuronal development and pathogenesis. J Biochem. 2016; 160(2):77–85. Epub 2016/06/19. https://doi.org/10.1093/jb/mvv037 [pii]. PMID: 27318359.

88. Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, et al. Hyperactive transforming growth factor-beta 1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res. 2013; 28(12):2476–89. Epub 2013/05/25. https://doi.org/10.1002/jbmr.1992 PMID: 23703870.

89. Caterina MJ, Pang Z. TRP Channels in Skin Biology and Pathophysiology. Pharmaceuticals (Basel). 2016; 9(4). Epub 2016/12/17. E77 [pii] ph9040077 [pii]. https://doi.org/10.3390/ph9040077 PMID: 27983625; PubMed Central PMCID: PMC5198052.

90. Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL. TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci. 2009; 29(15):4808–19. Epub 2009/04/17. https://doi.org/10.1523/JNEUROSCI.3580-08.2009 PMID: 19369549; PubMed Central PMCID: PMC2744291.

91. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000; 151(1):33–40. Epub 2000/01/07. PMID: 10625171.

92. Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017; 8(47):82037–48. Epub 2017/11/16. PMID: 28828537; PubMed Central PMCID: PMC5820292.

93. Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008; 10(11):1204–12. Epub 2008/10/28. PMID: 18953429; PubMed Central PMCID: PMC2570596.

94. Baron P, Kreider B. Axons induce differentiation of neurofibroma Schwann-like cells. Acta Neuro-pathol. 1991; 81(5):491–5. Epub 1991/01/01. PMID: 1713393.

95. Bennett DL, Boucher TJ, Armanini MP, Poulsen KT, Michael GJ, Priestley JV, et al. The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J Neurosci. 2000; 20(1):427–37. Epub 2000/01/11. PMID: 10627618.

96. JNEUROSCI.3649-04.2004 PMID: 15496660.

97. Jaffe BM, Betts S, Stucky CL. Activation of neuropeptide receptors by sensory nerve injury: possible role of target-derived neurotrophin factor family receptor components. J Neurosci. 2000; 20(1):427–37. Epub 2000/01/11. PMID: 10627618.

98. Jaycox SM, Pletnicki A, Fischmeister R, Patrick J, Stacey K, Figurelli M, et al. Interaction between Schwann cells and sensory neurons after nerve transection and regeneration: possible role of target-derived neurotrophic factor signaling. J Neurosci. 2009; 29(6):1636–47. Epub 2009/02/13. https://doi.org/10.1523/JNEUROSCI.3474-08.2009 PMID: 19211871; PubMed Central PMCID: PMC2788416.

99. Wang T, Molliver DC, Jing X, Schwartz ES, Yang FC, Samad OA, et al. Phenotypic switching of non-peptidergic cutaneous sensory neurons following peripheral nerve injury. PLoS One. 2011; 6(12):e28908. Epub 2012/01/05. https://doi.org/10.1371/journal.pone.0028908 [pii]. PMID: 22216140; PubMed Central PMCID: PMC3244441.

100. Rice FL, Rasmusson DD. Innervation of the digit on the forepaw of the raccoon. J Comp Neurol. 2000; 417(4):467–90. Epub 2000/03/04. https://doi.org/10.1002/(SICI)1096-9861(20000221)417:4<467::AID-CNE6>3.0.CO;2-O [pii]. PMID: 10701867.

101. Ridley AJ, Davis JB, Stroobant P, Land H. Transforming growth factors-beta 1 and beta 2 are mitogens for rat Schwann cells. J Cell Biol. 1989; 109(6 Pt 2):3419–24. Epub 1989/12/01. https://doi.org/10.1083/jcb.109.6.3419 PMID: 2557356; PubMed Central PMCID: PMC2115905.

102. Schubert D. Synergistic interactions between transforming growth factor beta and fibroblast growth factor regulate Schwann cell mitosis. J Neurobiol. 1992; 23(2):143–6. Epub 1992/03/01. https://doi.org/10.1002/neu.480230205 PMID: 1527524.

103. Torres KC, Lima G, Simoes ESAC, Lubambo I, Rodrigues LO, Rodrigues L, et al. Immune markers in the RASopathy neurofibromatosis type 1. J Neuroimmunol. 2016; 295–296:122–3. Epub 2016/05/29. https://doi.org/10.1016/j.jneuroim.2016.04.006 [pii]. PMID: 27235357.

104. Jacob C. Transcriptional control of neural crest specification into peripheral glia. Glia. 2015. Epub 2015/03/11. https://doi.org/10.1002/glia.22816 PMID: 25752517.

105. Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci. 2005; 6(9):671–82. Epub 2005/09/02. nm1746 [pii] https://doi.org/10.1038/nrn1746 PMID: 16136171.
Aquino JB, Sierra R. Schwann cell precursors in health and disease. Glia. 2018; 66(3):465–76. Epub 2017/11/11. https://doi.org/10.1002/glia.23262 PMID: 29124786.

Biernaskie JA, McKenzie IA, Toma JG, Miller FD. Isolation of skin-derived precursors (SKPs) and differentiation and enrichment of their Schwann cell progeny. Nat Protoc. 2006; 1(6):2803–12. Epub 2007/04/05. nprot.2006.422 [pii] https://doi.org/10.1038/nprot.2006.422 PMID: 17406538.

Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, Barnabe-Heider F, et al. A dermal niche for multipotent adult skin-derived precursor cells. Nat Cell Biol. 2004; 6(11):1082–93. Epub 2004/11/02. ncb1181 [pii] https://doi.org/10.1038/ncb1181 PMID: 15517002.

Fernandes KJ, Miller FD. Isolation, expansion, and differentiation of mouse skin-derived precursors. Methods Mol Biol. 2009; 482:159–70. Epub 2008/12/18. https://doi.org/10.1007/978-1-59745-060-7_10 PMID: 19089355.

Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells. 2005; 23(6):727–37. Epub 2005/05/27. 23/6/727 [pii] https://doi.org/10.1634/stemcells.2004-0134 PMID: 15917469.

Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell. 2009; 4(5):453–63. Epub 2009/05/12. https://doi.org/10.1016/j.stem.2009.03.017 [pii] PMID: 19427294; PubMed Central PMCID: PMC2737469.

Maro GS, Vermeren M, Voiculescu O, Melton L, Cohen J, Charnay P, et al. Neural crest boundary cap cells constitute a source of neuronal and glial cells of the PNS. Nat Neurosci. 2004; 7(9):930–8. Epub 2004/08/24. https://doi.org/10.1038/nn1299 PMID: 15322547.

Aquino JB, Hjerling-Leffler J, Koltzenburg M, Edlund T, Villar MJ, Emfors P. In vitro and in vivo differentiation of boundary cap neural crest stem cells into mature Schwann cells. Exp Neurol. 2006; 198(2):438–49. Epub 2006/01/31. S0014-4886(05)00471-1 [pii] https://doi.org/10.1016/j.expneurol.2005.12.015 PMID: 16442526.

Couplier F, Le Crom S, Maro GS, Manent J, Giovannini M, Maciorowski Z, et al. Novel features of boundary cap cells revealed by the analysis of newly identified molecular markers. Glia. 2009; 57(13):1450–7. Epub 2009/02/27. https://doi.org/10.1002/glia.20862 PMID: 19243017.

Gresset A, Couplier F, Gerschenfeld G, Jourdon A, Matesic G, Richard L, et al. Boundary Caps Give Rise to Neurogenic Stem Cells and Terminal Glia in the Skin. Stem Cell Reports. 2015; 5(2):278–90. Epub 2015/07/28. https://doi.org/10.1016/j.stemcr.2015.06.005 [pii] PMID: 26212662; PubMed Central PMCID: PMC4618659.

Radomska KJ, Topilko P. Boundary cap cells in development and disease. Curr Opin Neurobiol. 2017; 47:209–15. Epub 2017/11/11. https://doi.org/10.1016/j.conb.2017.11.003 PMID: 29174469.

Radomska KJ, Couplier F, Gresset A, Schmitt A, Debibche A, Lemoine S, et al. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells. Cancer Discov. 2019; 9(1):130–47. Epub 2018/10/24. https://doi.org/10.1158/2159-8290.CD-18-0156 PMID: 30348676.

Carrero G. Fascicular anatomy, nervi nervorum, and paresthesia. Reg Anesth Pain Med. 2003; 28(1):72–3; author reply 3. Epub 2003/02/05. S1098733902277159 [pii] PMID: 12567353.

Bove GM, Light AR. Calcitonin gene-related peptide and peripherin immunoreactivity in nerve sheaths. Somatosens Mot Res. 1995; 12(1):49–57. Epub 1995/01/01. PMID: 7571942.

Dhital K, Lincoln J, Appenzeller O, Burnstock G. Adrenergic innervation of vasa and nervi nervorum of optic, sciatic, vagus and sympathetic nerve trunks in normal and streptozotocin-diabetic rats. Brain Res. 1986; 367(1–2):39–44. Epub 1986/03/05. 0006-8993(86)91576-3 [pii] PMID: 2938665.

Vilensky JA, Gilman S, Casey K. Sir Victor Horsley, Mr John Marshall, the nervi nervorum, and pain: more than a century ahead of their time. Arch Neurol. 2005; 62(3):499–501. Epub 2005/03/16. 62/3/499 [pii] https://doi.org/10.1001/archneur.62.3.499 PMID: 15767520.

Liao CP, R CB, Brossseau JP, Chen Z, Mo J, Tchegnon E, et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest. 2018. Epub 2018/03/30. https://doi.org/10.1172/JCI9942499442 [pii] PMID: 29596064.

Jankowski MP, Baumbauer KM, Wang T, Albers KM, Davis BM, Koerber HR. Cutaneous neuritun overexpression alters mechanical, thermal, and cold responsiveness in physiologically identified primary afferent fibers. J Neurophysiol. 2017; 117(3):1258–65. Epub 2016/12/31. https://doi.org/10.1152/jn.00731.2016 PMID: 280531403; PubMed Central PMCID: PMC55349329.

Iwase T, Jung CG, Bae H, Zhang M, Soliven B. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J Neurochem. 2005; 94(6):1488–99. Epub 2005/08/10. JNC3290 [pii] https://doi.org/10.1111/j.1471-4159.2005.03280.x PMID: 16086701.
125. Pirzoo M, Kaljas A, Tamk K, Timmus T. Expression of NGF and GDNF family members and their receptors during peripheral nerve development and differentiation of Schwann cells in vitro. Neurosci Lett. 2010; 469(1):135–40. Epub 2009/12/01. https://doi.org/10.1016/j.neulet.2009.11.060 [pii]. PMID: 19944473; PubMed Central PMCID: PMC2808476.

126. Park S, Hong YW. Transcriptional regulation of artemin is related to neurite outgrowth and axin polymerization in mature DRG neurons. Neurosci Lett. 2006; 404(1–2):61–6. Epub 2006/06/20. S0304-3908(06)00528-3 [pii]. https://doi.org/10.1016/j.neulet.2006.05.041 PMID: 16781061.

127. Leitner ML, Molliver DC, Osborne PA, Vejasea R, Golden JP, Lampe PA, et al. Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci. 1999; 19(21):9322–31. Epub 1999/10/26. PMID: 10531437.

128. Terenghi G. Peripheral nerve regeneration and neurotrophic factors. J Anat. 1999; 194 (Pt 1):1–14. Epub 1999/05/05. https://doi.org/10.1046/j.1469-7580.1999.19410001.x PMID: 10227662; PubMed Central PMCID: PMC1467889.

129. Wang S, Elitt CM, Malin SA, Albers KM. Effects of the neurotrophic factor artemin on sensory afferent development and sensitivity. Sheng Li Xue Bao. 2008; 60(5):585–70. Epub 2008/10/30. PMID: 18958361; PubMed Central PMCID: PMC2805118.

130. Riccardi VM, Powell PP. Denervation in von Recklinghausen’s neurofibromatosis (NF-1) leads to fewer and smaller neurofibromas. Neurology. 1988; 38:1810.

131. Jankowski MP, Rau KK, Soneji DJ, Anderson CE, Koerber HR. Enhanced artemin/GFRalpha3 levels regulate mechanically insensitive, heat-sensitive C-fiber recruitment after axotomy and regeneration. J Neurosci. 2010; 30(48):16272–83. Epub 2010/12/03. https://doi.org/10.1523/JNEUROSCI.2195-10.2010 [pii]. PMID: 21233573; PubMed Central PMCID: PMC3018779.

132. Kupari J, Airaksinen MS. Different requirements for GFRalpha2-sIGNALING in three populations of cutaneous sensory neurons. PLoS One. 2014; 9(8):e104764. Epub 2014/08/12. https://doi.org/10.1371/journal.pone.0104764 [pii]. PMID: 25111170; PubMed Central PMCID: PMC4128720.

133. Wilson SR, Bautista DM. Role of Transient Receptor Potential Channels in Acute and Chronic Itch. J Biomed Sci. 2018; 25(1):46. Epub 2018/05/26. https://doi.org/10.1186/s12929-018-0448-y [pii]. PMID: 29793480; PubMed Central PMCID: PMC5966886.

134. Ribeiro S, Napoli I, White IJ, Parrinello S, Flanagan AM, Suter U, et al. Injury signals cooperate with mechanically insensitive, heat-sensitive C-fiber recruitment after axotomy and regeneration. J Neurosci. 2012; 32(49):17869–73. Epub 2012/12/12. https://doi.org/10.1523/JNEUROSCI.2323-12.2012 PMID: 23223305; PubMed Central PMCID: PMC3417484.

135. Cheng YR, Jiang BY, Chen CC. Acid-sensing ion channels: dual function proteins for chemosensing and mechano-sensing. J Biomed Sci. 2018; 25(1):46. Epub 2018/05/26. https://doi.org/10.1186/s12929-018-0448-y [pii]. PMID: 29793480; PubMed Central PMCID: PMC5966886.

136. Leitner ML, Molliver DC, Osborne PA, Vejasea R, Golden JP, Lampe PA, et al. Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci. 1999; 19(21):9322–31. Epub 1999/10/26. PMID: 10531437.

137. Kupari J, Airaksinen MS. Different requirements for GFRalpha2-sIGNALING in three populations of cutaneous sensory neurons. PLoS One. 2014; 9(8):e104764. Epub 2014/08/12. https://doi.org/10.1371/journal.pone.0104764 [pii]. PMID: 25111170; PubMed Central PMCID: PMC4128720.

138. Cauna N. Fine morphological characteristics and microtopography of the free nerve endings of the human digital skin. Anat Rec. 1980; 198(4):643–56. Epub 1980/12/01. https://doi.org/10.1002/ar.10919800409 PMID: 7212314.

139. Cheng YR, Jiang BY, Chen CC. Acid-sensing ion channels: dual function proteins for chemosensing and mechano-sensing. J Biomed Sci. 2018; 25(1):46. Epub 2018/05/26. https://doi.org/10.1186/s12929-018-0448-y [pii]. PMID: 29793480; PubMed Central PMCID: PMC5966886.

140. Ribeiro S, Napoli I, White IJ, Parrinello S, Flanagan AM, Suter U, et al. Injury signals cooperate with mechanically insensitive, heat-sensitive C-fiber recruitment after axotomy and regeneration. J Neurosci. 2012; 32(49):17869–73. Epub 2012/12/12. https://doi.org/10.1523/JNEUROSCI.2323-12.2012 PMID: 23223305; PubMed Central PMCID: PMC3417484.

141. Albrecht PJ, Rice FL. Fibromyalgia syndrome pathology and environmental influences on affictions with medically unexplained symptoms. Rev Environ Health. 2016; 31(2):281–94. Epub 2016/04/23. https://doi.org/10.1515/reveh-2015-0040 [pii]/reveh-ahead-of-print/reveh-2015-0040/reveh-20150040.xml [pii]. PMID: 27105483.

142. Karvonen SL, Kallioinen M, Ylä-Outinen H, Peltonen J, Olkinen A. Occult neurofibromas and increased S-100 protein in the skin of patients with Neurofibromatosis type 1. New insights to the etiopathomechanism of neurofibromas. Archives of Dermatology. 2000; 136:1207–9. PMID: 11030766.